Open Access Open Access  Restricted Access Subscription or Fee Access

Comprehensive Approach for Treatment of Alzheimer's and Parkinson's Disease

Neelam Balekar, kirti Pande, kirti Pande

Abstract


The two most prevalent illnesses in the world, Alzheimer's and Parkinson's disease, affect 44 million people globally and are expected to increase by 2050. While current treatments for Alzheimer’s and Parkinson's disease are primarily symptomatic, with drugs like aducanumab offering only limited disease progression, complementary therapies like mindfulness meditation may provide mental clarity and relaxation. This review aims to evaluate various treatment approaches for Alzheimer’s and Parkinson’s, including non-pharmacological options like deep brain stimulation and complementary therapy like mindfulness meditation, which can aid in symptomatic relief for conditions such as anxiety, depression, cognitive function, and sleep disturbances. While pharmacological approaches remain the primary mode of treatment, mindfulness meditation offers promise for further research with larger sample sizes.

Full Text:

PDF

References


Kiper K, Freeman JL. Use of Zebrafish Genetic Models to Study Etiology of the Amyloid-Beta and Neurofibrillary Tangle Pathways in Alzheimer's Disease. Curr Neuropharmacol. 2022;20(3):524-39.

Cacabelos R. What Have We Learnt from Past Failures in Alzheimer's Disease Drug Discovery? Expert Opin Drug Discov. 2022;17(4):309-23.

Dai CL, Liu F, Iqbal K, Gong CX. Gut Microbiota and Immunotherapy for Alzheimer's Disease. Int J Mol Sci. 2022 ;23(23):15230:1-25.

Miculas DC, Negru PA, Bungau SG, Behl T, Hassan SSU, Tit DM. Pharmacotherapy Evolution in Alzheimer's Disease: Current Framework and Relevant Directions. Cells. 2022 ;12(1):131:1-17.

Fonte C, Smania N, Pedrinolla A, Munari D, Gandolfi M, Picelli A, Varalta V, Benetti MV, Brugnera A, Federico A, Muti E, Tamburin S, Schena F, Venturelli M. Comparison between physical and cognitive treatment in patients with MCI and Alzheimer's disease. Aging (Albany NY). 2019 ;11(10):3138-155.

Hu D, Jin Y, Hou X, Zhu Y, Chen D, Tai J, Chen Q, Shi C, Ye J, Wu M, Zhang H, Lu Y. Application of Marine Natural Products against Alzheimer's Disease: Past, Present and Future. Mar Drugs. 2023 ;21(1):43:1-25.

Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G. Therapies for Prevention and Treatment of Alzheimer's Disease. Biomed Res Int. 2016; 2016:2589276:1-17.

MacMillan C. Lecanemab, the New Alzheimer’s Treatment: 3 Things to Know. Yale Medicine [Internet].; 2023 Jan Available from: https://www.yalemedicine.org/news/lecanemab-leqembi-new-alzheimers-drug.

Woloshin S, Kesselheim AS. What to Know About the Alzheimer Drug Aducanumab (Aduhelm).JAMA Intern Med. 2022;182(8):892.

Cona L. Stem Cell Therapy for Alzheimer's: Latest Findings and Treatments. DVC Stem.Advanced Stem Cell Therapy Clinic [Internet].; 2023 Feb 15 [cited 2023 Mar 3]. Available from:https://www.dvcstem.com/post/stem cell-therapy-for-alzheimers.

Rizek P, Kumar N, Jog MS. An Update on the Diagnosis and Treatment of Parkinson Disease.CMAJ. 2016 ;188(16):1157-165.

Di Luca DG, Reyes NGD, Fox SH. Newly Approved and Investigational Drugs for MotorSymptom Control in Parkinson's Disease. Drugs. 2022 ;82(10):1027-53.

Stoker TB, Torsney KM, Barker RA. Emerging Treatment Approaches for Parkinson's Disease.Front Neurosci. 2018 ;12:693:1-10.

Vidović M, Rikalovic MG. Alpha-Synuclein Aggregation Pathway in Parkinson's Disease:Current Status and Novel Therapeutic Approaches. Cells. 2022;11(11):1732:1-31.

Church FC. Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease. Biomolecules. 2021 ;11(4):612:2-17.

Hauser RA, LeWitt PA, Comella CL. On Demand Therapy for Parkinson's Disease Patients: Opportunities and choices. Postgrad Med. 2021 ;133(7):721-27.

Jankovic J, Tan EK. Parkinson's Disease: Etiopathogenesis and Treatment. J Neurol Neurosurg Psychiatry. 2020 ;91(8):795-808.

Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. Recent Advances in Drug Therapy for Parkinson's Disease. Intern Med. 2023 ;62(1):33-42.

Fan HX, Sheng S, Zhang F. New Hope for Parkinson's Disease Treatment: Targeting Gut Microbiota. CNS Neurosci Ther. 2022 ;28(11):1675-88.

Stoker TB, Barker RA. Recent Developments in the Treatment of Parkinson's Disease. F1000Res. 2020;9:F1000 Faculty Rev-862: 1-12.

Tang YY, Hölzel BK, Posner MI. The neuroscience of mindfulness meditation. Nat Rev Neurosci. 2015 Apr;16(4):213-25.

Hoge EA, Bui E, Palitz SA, Schwarz NR, Owens ME, Johnston JM, et al. The Effect of Mindfulness Meditation Training on Biological Acute Stress Responses in Generalized Anxiety Disorder. Psychiatry Res. 2018;262:328–32.

Russell-Williams J, Jaroudi W, Perich T, Hoscheidt S, El Haj M, Moustafa AA. Mindfulness and Meditation: Treating Cognitive Impairment and Reducing Stress in Dementia. Rev Neurosci. 2018 25;29(7):791-804.

Nascimento ALCS, Fernandes RP, Carvalho ACS, Frigieri I, Alves RC, Chorilli M. Insights for Alzheimer's Disease Pharmacotherapy and Current Clinical Trials. Neurochem Int. 2022; 159:105401.

Shen H, Chen M, Cui D. Biological Mechanism Study of Meditation and its Application in Mental Disorders. Gen Psychiatr. 2020 ;33(4): e100214.

Nourollahimoghadam E, Gorji S, Gorji A, Khaleghi Ghadiri M. Therapeutic Role of Yoga in Neuropsychological Disorders. World J Psychiatry. 2021 Oct 19;11(10):754-73.

Dissanayaka NN, Idu Jion F, Pachana NA, O'Sullivan JD, Marsh R, Byrne GJ, Harnett P. Mindfulness for Motor and Nonmotor Dysfunctions in Parkinson's Disease. Parkinsons Dis. 2016;2016:7109052:1-13.




DOI: https://doi.org/10.37591/rrjols.v13i1.3670

Refbacks

  • There are currently no refbacks.